MERCK 401 (k) RETIREMENT SAVINGS PLANS

On March 30, 2008 it was announced that Vytorin, a combination of the anti-cholesterol drugs simvastatin and Zetia, which was marketed by Merck & Co., Inc. (Merck) (NYSE: MRK), was no more effective than simvastatin alone, which is available in a substantially cheaper generic form. When the truth was revealed, Merck's stock price fell drastically, resulting in massive losses to participants in the Merck & Co., Inc. Employee Savings & Security Plan (the Salaried Plan), the Merck & Co., Inc. Employee Stock Purchase & Savings Plan (the Hourly Plan), the Merck Puerto Rico Employee Savings & Security Plan (the Puerto Rico Plan) and the Merck-Medco Managed Care, LLC 401(k) Savings Plan (the Medco Plan) (collectively the Plans).

The investigation concerns violations of the Employee Retirement Income Security Act (ERISA) and breach of fiduciary duty claims against Defendants arising from improprieties relating to Vytorin and whether Defendants negligently failed to disclose material information about the effects of Vytorin necessary for participants to make informed decisions concerning their investments in the Merck Common Stock Fund (the Fund). A breach of ERISA-mandated fiduciary duties of loyalty and prudence to participants and beneficiaries of the Plans may have occurred if the fiduciaries failed to manage the assets of the Plans prudently and loyally by investing the in the Fund when it was no longer prudent for participants' retirement savings.

Merck employees who own Merck stock or the Fund through the Plans may be able to recover some of their losses. If you or anyone you know is a member of the Plans, please complete a Merck Complaint Form for a free evaluation.

Merck Employee Savings Plan Legal Help

If you have suffered losses to your Merck employee plan, please click the link below to send your complaint to a lawyer to evaluate your claim at no cost or obligation.
Last updated on Jul-11-08